▎WuXi AppTec Content Team Report
On May 7, Argo Biopharma announced itsBW-01 for Severe HypertriglyceridemiaThe first subject dosing of the Phase 2 clinical trial was completed on April 29, 2024. BW-01 is a self-developed product by Argo.A New Cardiovascular siRNA (Small Interfering Nucleic Acid Drug)。siRNA drugs are an emerging new technology drug in recent years, with the advantages of numerous druggable targets, potent efficacy, good safety, and low dosing frequency. The range of indications is extensive, covering cardiovascular diseases, rare diseases, neurological disorders, viral hepatitis, ophthalmic diseases, cancer, and more. This field has become one of the most promising frontier areas in the global pharmaceutical industry.Argo Biopharma was founded in 2021 as a clinical-stage biotechnology company dedicated to developing the next generation of siRNA drugs to provide better treatment options for patients worldwide. In November 2023, Argo Biopharma announced the completion of a 300 million RMB financing.Series A+ FinancingThis round of financing was led by SDIC Capital, with Huagai Capital, Yuanxi Haihe Fund, and existing shareholder Sanyi Innovation Investment participating.Over the past nearly three years, Argo Biopharma has built a product pipeline comprising multiple siRNA candidate drugs, covering a wide range of indications.Currently, Argo has 5 siRNA drugs in clinical trial stages.。Notably, in January 2024, Argo Biopharma announced that it had reached multiple RNAi project licensing and strategic agreements with Novartis.Cooperation AgreementAccording to the agreement, Argo Biopharma will receive an upfront payment of $185 million from Novartis, as well as milestone payments with a total potential transaction value of nearly $4.2 billion and tiered royalties on commercial sales.This article comes fromCompiled and edited by the WuXi AppTec content team based on publicly available information. Individuals are welcome to share this content on their social media feeds. For authorization to repost, please contact us via a message on the "MedView" WeChat Official Account. For other collaboration inquiries, please contact wuxi_media@wuxiapptec.com.
Disclaimer: The content team of WuXi AppTec focuses on introducing the research progress in global biopharmaceuticals and health. This article is for information exchange only, and the views expressed in the article do not represent the position of WuXi AppTec, nor does it imply that WuXi AppTec supports or opposes these views. This article is not a recommendation for treatment plans. For guidance on treatment options, please visit a正规 hospital.
